CollPlant Biotechnologies Ltd. Sponsored ADR (NASDAQ:CLGN) Short Interest Update

CollPlant Biotechnologies Ltd. Sponsored ADR (NASDAQ:CLGN) saw a large decrease in short interest in the month of July. As of July 15th, there was short interest totaling 16,240 shares, a decrease of 51.8% from the June 30th total of 33,721 shares. Based on an average daily volume of 29,266 shares, the days-to-cover ratio is currently 0.6 days. Approximately 0.1% of the company’s shares are sold short.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised CollPlant Biotechnologies from a “sell (e)” rating to a “sell (e+)” rating in a research report on Monday, June 8th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, CollPlant Biotechnologies has a consensus rating of “Hold” and an average target price of $11.50.

Institutional Investors Weigh In On CollPlant Biotechnologies

A hedge fund recently raised its position in CollPlant Biotechnologies stock. Villere ST Denis J & Co. LLC boosted its position in shares of CollPlant Biotechnologies Ltd. Sponsored ADR (NASDAQ:CLGN) by 3.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 607,300 shares of the company’s stock after buying an additional 18,583 shares during the period. Villere ST Denis J & Co. LLC owned 4.75% of CollPlant Biotechnologies worth $850,000 at the end of the most recent quarter. Institutional investors and hedge funds own 21.69% of the company’s stock.

CollPlant Biotechnologies Price Performance

CollPlant Biotechnologies stock traded up $0.00 during trading hours on Tuesday, hitting $0.32. 6,046 shares of the stock traded hands, compared to its average volume of 79,975. The stock has a market capitalization of $4.64 million, a price-to-earnings ratio of -0.22 and a beta of 1.60. CollPlant Biotechnologies has a 1 year low of $0.27 and a 1 year high of $3.23. The firm’s 50 day moving average price is $0.36 and its 200-day moving average price is $0.64.

CollPlant Biotechnologies (NASDAQ:CLGN) last posted its quarterly earnings results on Saturday, May 30th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.01. CollPlant Biotechnologies had a negative net margin of 683.68% and a negative return on equity of 218.81%. The company had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.46 million.

About CollPlant Biotechnologies

CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) is a regenerative medicine company that develops and commercializes recombinant human collagen (rhCollagen) and 3D bioprinting technologies for medical and aesthetic applications. The company’s proprietary plant-based rhCollagen is produced using genetically engineered tobacco plants to provide a scalable, animal-free source of human collagen that meets regulatory standards.

CollPlant’s product portfolio includes Vergenix™ wound care matrices and dermal fillers for aesthetic and reconstructive purposes, as well as a range of bioinks designed for 3D bioprinting of soft and hard tissues.